Chimerix, Inc. (NASDAQ:CMRX) Expected to Earn Q1 2025 Earnings of ($0.23) Per Share

Chimerix, Inc. (NASDAQ:CMRX) – Stock analysts at Wedbush issued their Q1 2025 earnings estimates for Chimerix in a report issued on Wednesday, May 1st. Wedbush analyst D. Nierengarten anticipates that the biopharmaceutical company will post earnings per share of ($0.23) for the quarter. Wedbush currently has a “Outperform” rating and a $6.00 target price on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.77) per share. Wedbush also issued estimates for Chimerix’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.24) EPS and Q4 2025 earnings at ($0.23) EPS.

Chimerix (NASDAQ:CMRX) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Chimerix had a negative return on equity of 39.62% and a negative net margin of 25,337.96%. During the same period in the prior year, the firm earned ($0.24) EPS.

A number of other equities analysts have also commented on the stock. StockNews.com lowered shares of Chimerix from a “hold” rating to a “sell” rating in a research report on Friday. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Chimerix in a research report on Friday, March 1st.

Chimerix Stock Performance

NASDAQ:CMRX opened at $0.95 on Friday. Chimerix has a 52-week low of $0.88 and a 52-week high of $1.57. The business’s fifty day moving average is $1.04 and its 200 day moving average is $1.00. The firm has a market cap of $85.41 million, a price-to-earnings ratio of -1.02 and a beta of 1.13.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CMRX. Vance Wealth Inc. purchased a new position in Chimerix in the fourth quarter worth about $46,000. Pale Fire Capital SE purchased a new position in shares of Chimerix in the third quarter worth $95,000. Assenagon Asset Management S.A. boosted its stake in shares of Chimerix by 167.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 426,672 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 267,044 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Chimerix by 190.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock valued at $568,000 after purchasing an additional 387,638 shares during the period. Finally, Vestal Point Capital LP purchased a new position in shares of Chimerix in the fourth quarter worth approximately $1,348,000. 45.42% of the stock is owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.